Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Marchou

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
Histopathology|July 1, 1994
bcl-2 proto-oncogene and Epstein-Barr virus latent membrane protein-1 expression in AIDS-related lymphomaD Schlaifer, P Brousset, M Attal, et al.
The Journal of Infectious Diseases|July 1, 1995
A 3-week hepatitis B vaccination schedule provides rapid and persistent protective immunity: a multicenter, randomized trial comparing accelerated and classic vaccination schedulesB Marchou, J L Excler, C Bourderioux, et al.
Journal of Acquired Immune Deficiency Syndromes|May 1, 1994
Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a prospective, randomized, controlled clinical trial. LFPMI Study Group. Ligue Française de Prévention des Maladies InfectieusesT May, C Beuscart, J Reynes, et al.
Medecine Et Maladies Infectieuses|December 3, 2009
[Impact of malaria on HIV infection]G Martin-Blondel, M Soumah, B Camara, et al.
Medecine Et Maladies Infectieuses|October 28, 2008
[Hyperreactive malarial splenomegaly: three clinical cases and literature review]B Camara, J-B Kantambadouno, G Martin-Blondel, et al.
Vaccine|November 1, 1993
Three-week hepatitis B vaccination provides protective immunityB Marchou, N Picot, P Chavanet, et al.
The Journal of Parasitology|July 1, 2005
Ex vivo and in vitro impairment of CD36 expression and tumor necrosis factor-alpha production in human monocytes in response to Plasmodium falciparum-parasitized erythrocytesA Berry, G Chene, F Benoit-Vical, et al.
International Journal of Radiation Oncology, Biology, Physics|May 20, 1998
Low-dose splenic irradiation in the treatment of immune thrombocytopenia in HIV-infected patientsF Soum, J A Trille, J C Auvergnat, et al.
Antimicrobial Agents and Chemotherapy|November 18, 2000
Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study GroupM Savès, F Raffi, P Clevenbergh, et al.
HIV Medicine|March 7, 2013
Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptionsM Winnock, F Bani-Sadr, E Pambrun, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Histopathology|July 1, 1994
bcl-2 proto-oncogene and Epstein-Barr virus latent membrane protein-1 expression in AIDS-related lymphomaD Schlaifer, P Brousset, M Attal, et al.
The Journal of Infectious Diseases|July 1, 1995
A 3-week hepatitis B vaccination schedule provides rapid and persistent protective immunity: a multicenter, randomized trial comparing accelerated and classic vaccination schedulesB Marchou, J L Excler, C Bourderioux, et al.
Journal of Acquired Immune Deficiency Syndromes|May 1, 1994
Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a prospective, randomized, controlled clinical trial. LFPMI Study Group. Ligue Française de Prévention des Maladies InfectieusesT May, C Beuscart, J Reynes, et al.
Medecine Et Maladies Infectieuses|December 3, 2009
[Impact of malaria on HIV infection]G Martin-Blondel, M Soumah, B Camara, et al.
Medecine Et Maladies Infectieuses|October 28, 2008
[Hyperreactive malarial splenomegaly: three clinical cases and literature review]B Camara, J-B Kantambadouno, G Martin-Blondel, et al.
Vaccine|November 1, 1993
Three-week hepatitis B vaccination provides protective immunityB Marchou, N Picot, P Chavanet, et al.
The Journal of Parasitology|July 1, 2005
Ex vivo and in vitro impairment of CD36 expression and tumor necrosis factor-alpha production in human monocytes in response to Plasmodium falciparum-parasitized erythrocytesA Berry, G Chene, F Benoit-Vical, et al.
International Journal of Radiation Oncology, Biology, Physics|May 20, 1998
Low-dose splenic irradiation in the treatment of immune thrombocytopenia in HIV-infected patientsF Soum, J A Trille, J C Auvergnat, et al.
Antimicrobial Agents and Chemotherapy|November 18, 2000
Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study GroupM Savès, F Raffi, P Clevenbergh, et al.
HIV Medicine|March 7, 2013
Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptionsM Winnock, F Bani-Sadr, E Pambrun, et al.
Pageof 8